Events

Avis De Sécurité sur Archer Super Stiff Guidewire

Selon ALIMS (Agencija za lekove i medicinska sredstva), ce/cet/cette avis de sécurité concerne un dispositif en/au/aux/à Serbia qui a été fabriqué par Medtronic Inc..

Qu'est-ce que c'est?

Les avis de sécurité sont des communications que les fabricants de dispositifs médicaux ou leurs représentants font parvenir en particulier aux travailleurs du secteur médical, mais aussi aux utilisateurs de ces dispositifs. Les avis de sécurité concernent les actions entreprises quant aux dispositifs présents sur le marché et peuvent inclure des rappels et des alertes.

En savoir plus sur les données ici
  • Type d'événement
    Field Safety Notice
  • Date de publication de l'événement
    2013-03-19
  • Pays de l'événement
    Serbia
  • Source de l'événement
    ALIMSA
  • URL de la source de l'événement
    https://www.alims.gov.rs/latin/2013/03/19/obavestenje-o-meri-povlacenja-sa-trzista-medicinskih-sredstava-archer-super-stiff-guidewire/
  • Notes / Alertes
    Serbian data is current through February 2018. All of the data comes from ALIMS (Agencija za lekove i medicinska sredstva), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Serbia.
  • Notes supplémentaires dans les données
  • Cause
    Metronic has identified an issue involving specific lot numbers, where a change in the manufacturing process has been identified as the cause for potential kinking and breaking at the proximal weld end of the outer spring coil during in-vivo use. as of february 1st, 2013, medtronic has received nine (9) reports involving 14 guidewires related to this issue; four (4) of these reports involved serious injury. there were no patient deaths and no additional reported clinical sequelae related to these reports.

Device

Archer Super Stiff Guidewire
  • Modèle / numéro de série
    Model: ARCSJ200WLot: GFWC1124; GFWC1506; GFWC2138; GFWC2652; GFWC2653; GFWD0353; GFWD0881; GFWD0882; GFWD2048; GFWD2049; GFWD2050; GFWD2051; GFWD2052; GFWE0743; GFWE0744; GFWE0745; GFWE0746; GFWE0747; GFWE3710; GFWE4272; GFWE4273; GFWE4274; GFWE4275; GFWF0143; GFWF0144; GFWF0147; GFWF0148; GFWF0149; GFWG0428; GFWG0429; GFWG0430; GFWG0431; GFWG0432; GFWG0433; GFWG0434; GFWH0333; GFWH0334; GFWH0335; GFWH0336; GFWH0337; GFWH0338; GFWI0190; GFWI0191; GFWI0192; GFWI0193; GFWI0194; GFWI0195; GFWJ0027; GFWJ0028; GFWJ0029; GFWJ2454; GFWJ2455; GFWJ2456; GFWJ2457; GFWJ2458; GFWK1910; GFWK1911; GFWL0370; GFWL2571; GFWL2572; GFXA0224;Model: ARCSJ260WLot: GFWC1501; GFWC1502; GFWC1503; GFWD0883; GFWD0884; GFWD3256; GFWE0752; GFWE0753; GFWE3711; GFWF0145; GFWF0150; GFWG0425; GFWG0426; GFWG0427; GFWH0344; GFWH0345; GFWI0201; GFWI0202; GFWI0203; GFWJ0418; GFWJ0419; GFWJ0420; GFWJ2461; GFWJ2462; GFWJ2464; GFWJ2465; GFWL0368; GFWL0369; GFWL0415; GFWL0416; GFXA0219; GFXA0220; GFXA0221; GFXA0222;Model: ARCDJ260WLot: GFWC1507; GFWC1508; GFWD0885; GFWE0750; GFWE0751; GFWF0142; GFWF0146; GFWG0423; GFWG0424; GFWH0331; GFWH0332; GFWI0186; GFWI0187; GFWI0188; GFWJ2449; GFWJ2450; GFWJ2451; GFWJ2452; GFWK1844
  • Manufacturer
    Medtronic Inc.

Manufacturer

Medtronic Inc.
  • Société-mère du fabricant (2017)
    Medtronic plc
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    ALIMSA